Literatur
- 1
Aalykke C, Lauritsen J M, Hallas J, Reinholdt S, Krogfelt K, Lauritsen K.
Helicobacter pylori
and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory
drugs: A case-control study.
Gastroenterology.
1999;
116
1305-1309
- 2
Agreus L, Svardsudd K, Nyren O, Tibblin G.
Irritable
bowel syndrome and dyspepsia in the general population: Overlap
and lack of stability over time.
Gastroenterology.
1995;
109
671-680
- 3
Allescher H D, Adler G, Hartung J, Manns M P, Riemann J F, Wienbeck M, Classen M.
Prospektive
epidemiologische Studie der Oberbauchbeschwerden (PRESTO).
Dtsch
Med Wschr.
1999;
16,124
443-50
- 4
Bianchi P orro
G, Parente F, Imbesi V, Montrone F, Caruso I.
Role
of Helicobacter pylori in ulcer healing and recurrence of gastric
and duodenal ulcers in longterm NSAID users. Response to omeprazole dual
therapy.
Gut.
1996;
39
22-26
- 5
Blum A L, Arnold R, Stolte M, Fischer M, Koelz H R.
Short
course acid suppressive treatment for patients with functional dyspepsia:
results depend on Helicobacter pylori status.
Gut.
2000;
47
473-480
- 6
Burget D W, Chiverton S G, Hunt R H.
Is
there an optimal degree of acid suppression for healing of duodenal
ulcers? A model of the relationship between ulcer healing and acid
suppression.
Gastroenterology.
1990;
99
345-351
- 7
Bytzer P, Hansen J M, de Schaffalitzky M uckadell OB.
Empirical
H2-blocker therapy or prompt endoscopy in management of dyspepsia.
Lancet.
1994;
343
811-816
- 8
Caspary W F, Arnold R, Bayerdörffer E, Behrens R, Birkner B, Braden B. et al .
Diagnostik
und Therapie der Helicobacter-pylori-Infektion. Leitlinien der Deutschen
Gesellschaft für Verdauungs- und Stoffwechselkrankheiten
.
Z Gastroenterol.
1996;
34
392-401
- 9
Chan F K, Sung J J, Chung S C, To K F, Yung M Y, Leung V K. et al .
Randomised
trial of eradication of Helicobacter pylori before non-steroidal
anti-inflammatory drug therapy to prevent peptic ulcers.
Lancet.
1997;
350
975-979
- 10
Chan F K, Sung J J, Suen R, Lee Y T, Wu J C, Leung W K. et al .
Does
eradication of Helicobacter pylori impair healing of nonsteroidal
anti-inflammatory drug associated bleeding peptic ulcers? A prospective
randomized study.
Aliment Pharmacol Ther.
1998;
12
1201-1205
- 11
Cullen D, Bardhan K D, Eisner M, Kogut D G, Peacock R A, Thomson J M. et al .
Primary
gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory
drug users.
Aliment Pharmacol Ther.
1998;
12
135-140
- 12
Finney J S, Kinnersley N, Hughes M, OŽBryan-Tear C G, Lothian J.
Metaanalysis
of antisecretory and gastrokinetic compounds in functional dyspepsia.
J
Clin Gastroenterol.
1998;
26
312-320
- 13
Fisher R S, Parkman H P.
Management
of nonulcer dyspepsia.
N Engl J Med.
1998;
339
1376-1381
- 14
Gisbert J P, González L, Calvet X, García N, López T, Roqué M, Gabriel R, Pajares J M.
Proton pump
inhibitor, clarithromycin and either amoxycillin or nitroimidazole:
A meta-analysis of eradication of Helicobacter pylori.
Aliment
Pharmacol Ther.
2000;
14
1319-1328
- 15
Goldstein J L.
Who
needs prophylaxis of nonsteroidal anti-inflammatory drug-induced
ulcers and what is optimal prophylaxis?.
Eur J Gastroenterol
Hepatol.
2000;
12
S11-S15
(Suppl 1))
- 16
Halter F, Miazza B, Brignoli R.
Cisapride
or cimetidine in the treatment of functional dyspepsia. Results
of a double-blind, randomized, Swiss multicentre study.
Scand
J Gastroenterol.
1994;
29
618-623
- 17
Hawkey C J.
Nonsteroidal
anti-inflammatory drug gastropathy.
Gastroenterology.
2000;
119
521-535
- 18
Hawkey C J, Karrasch J A, Szczepanski L, Walker D G, Barkun A, Swannell A J. et al
.
Omeprazole
compared with misoprostol for ulcers associated with nonsteroidal
antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced
Ulcer Management (OMNIUM) Study Group.
N Engl J Med.
1998;
338
727-734
- 19
Hawkey, CJ, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, Shahane A,
Quan H, Bolognese J, Mortensen E.
Comparison of the
effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and
placebo on the gastroduodenal mucosa of patients with osteoarthritis:
a randomized, double-blind, placebo-controlled trial. The Rofecoxib
Osteoarthritis Endoscopy Multinational Study Group.
Arthritis
Rheum.
2000;
43
370-377
- 20
Hawkey C J, Tulassay Z, Szczepanski L, van Rensburg C J, Filipowicz-Sosnowska A, Lanas A.
et al .
Randomised
controlled trial of Helicobacter pylori eradication in patients
on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter
Eradication for Lesion Prevention.
Lancet.
1998;
352
1016-1021
- 21
Holtmann G, Armstrong D, Poppel E, Bauerfeind A, Goebell H, Arnold R. et al .
Influence
of stress on the healing and relapse of duodenal ulcers. A prospective,
multicenter trial of 2109 patients with recurrent duodenal ulceration
treated with ranitidine. RUDER Study Group.
Scand J Gastroenterol.
1992;
27
917-923
- 22
Holtmann G, Talley N J.
Functional
dyspepsia. Current treatment recommendations.
Drugs.
1993;
45
918-930
- 23
Hopkins R J, Girardi L S, Turney E A.
Relationship
between Helicobacter pylori eradication and reduced duodenal and
gastric ulcer recurrence: A review.
Gastroenterology.
1996;
110
1244-1252
- 24
Huang J, Hunt R H.
The
importance of clarithromycin dose in the management of Helicobacter
pylori infection: A meta-analysis of triple therapies with a proton
pump inhibitor, clarithromycin and amoxycillin or metronidazole.
Aliment
Pharmacol Ther.
1999;
13
719-729
- 25
Jones R, Tait C, Sladen G, Weston-Baker J.
A
trial of a test-and-treat strategy for Helicobacter pylori positive
dyspeptic patients in general practice.
Int J Clin Pract.
1999;
53
413-416
- 26
Koelz H R, Bolten W, Dragosics B, Labenz J, Rösch W, Stolte M, Blum A.
Primary
prophylaxis of NSAID-induced gastroduodenal ulcers and dyspepsia
in H. pylori-positive patients: Randomised, double-blind, placebo-controlled
treatment of of h. pylori infection vs. omeprazole.
Gastroenterology.
2000;
Abs. 1456
- 27
Kovacs T O, Campbell D, Haber M, Rose P, Jennings D E, Richter J.
Double-blind comparison
of lansoprazole 15 mg, lansoprazole 30 mg, and
placebo in the maintenance of healed gastric ulcer.
Dig Dis
Sci.
1998;
43
779-785
- 28
Kovacs T O, Campbell D, Richter J, Haber M, Jennings D E, Rose P.
Double-blind comparison
of lansoprazole 15 mg, lansoprazole 30 mg and
placebo as maintenance therapy in patients with healed duodenal
ulcers resistant to H2-receptor antagonists.
Aliment Pharmacol
Ther.
1999;
13
959-967
- 29
Labenz J, Peitz U, Köhl H, Kaiser J, Malfertheiner P, Hackelsberger A. et al .
Helicobacter
pylori increases the risk of peptic ulcer bleeding: A case-control
study.
Ital J Gastroenterol Hepatol.
1999;
31
110-115
- 30
Laine L, Schoenfeld P, Fennerty M B.
Therapy for
Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis
of randomized, controlled trials.
Ann Intern Med.
2001;
134
361-369
- 31
Lanas A, Bajador E, Serrano P, Fuentes J, Carreno S, Guardia J. et al .
Nitrovasodilators, low-dose aspirin, other
nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal
bleeding.
N Engl J Med.
2000;
343
834-839
- 32
Lassen A T, Pedersen F M, Bytzer P, de Schaffalitzky M uckadell OB.
Helicobacter
pylori test-and-eradicate versus prompt endoscopy for management
of dyspeptic patients: A randomised trial.
Lancet.
2000;
356
455-460
- 33
Lauritsen K, Rutgersson K, Bolling E, Brunner G, Eriksson S, Galmiche J P. et al .
Omeprazole
and ranitidine in the prevention of relapse in patients with duodenal
ulcer disease.
Can J Gastroenterol.
1999;
13
806-813
- 34
Lind T, Rydberg L, Kyleback A, Jonsson A, Andersson T, Hasselgren G. et al .
Esomeprazole provides improved acid control
vs. omeprazole In patients with symptoms of gastro-oesophageal reflux
disease.
Aliment Pharmacol Ther.
2000;
14
861-867
- 35
Malfertheiner P, Fischbach W, Layer P, Moessner J, Stolte M, Leodolter A, Demleitner K,
Fuchs W.
ELAN study proves symptomatic benefit
of Helicobacter pylori eradication in functional dyspepsia (FD).
Gastroenterology.
2000;
118
2421
- 36
Malfertheiner P, Labenz J.
Does Helicobacter pylori
status affect nonsteroidal anti-inflammatory drug-associated gastroduodenal pathology?.
Am
J Med.
1998;
104
35S-40S
- 37
Malfertheiner P, Leodolter A, Peitz U.
Cure
of Helicobacter pylori-associated ulcer disease through eradication.
Baillieres
Best Pract Res Clin Gastroenterol.
2000;
14
119-132
- 38
Malfertheiner P, Megraud F, O’Morain C. et al .
Current European concepts in the management
of Helicobacter pylori infection. The Maastricht Consensus Report:
European Helicobacter Pylori Study Group.
Gut.
1997;
41
8-13
- 39
Massimo C laar
G, Monaco S, Del V eccho
BC, Capurso L, Fusillo M, Annibale B.
Omeprazole 20 or 40 mg
daily for healing gastroduodenal ulcers in patients receiving non-steroidal
anti-inflammatory drugs.
Aliment Pharmacol Ther.
1998;
12
463-468
- 40
Mertz H, Fass R, Kodner A, Yan-Go F, Fullerton S, Mayer E A.
Effect of
amitriptyline on symtoms, sleep and visceral perception in patients
with functional dyspepsia.
Am J Gastroenterol.
1998;
93
160-165
- 41
Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M. et
al .
Systematic review and economic evaluation of Helicobacter
pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia
Review Group.
BMJ.
2000;
321
659-664
- 42
Patel P, Khulusi S, Mendall M A, Lloyd R, Jazrawi R, Maxwell J D. et al .
Prospective screening of dyspeptic patients
by Helicobacter pylori serology.
Lancet.
1995;
346
1315-1318
- 43
Peitz U, Hackelsberger A, Malfertheiner P.
A practical approach
to patients with refractory Helicobacter pylori infection, or who
are re-infected after standard therapy.
Drugs.
1999;
57
905-920
- 44
Richardson P, Hawkey C J, Stack W A.
Proton
pump inhibitors. Pharmacology and rationale for use in gastrointestinal
disorders.
Drugs.
1998;
56
307-35
- 45
Simon L S, Weaver A L, Graham D Y, Kivitz A J, Lipsky P E, Hubbard R C, Isakson P C,
Verburg K M, Yu S S, Zhao W W, Geis G S.
Anti-inflammatory
and upper gastrointestinal effects of celecoxib in rheumatoid arthritis:
a randomized controlled trial.
JAMA.
1999;
282
1921-1928
- 46
Soll A H.
Consensus
conference. Medical treatment of peptic ulcer disease. Practice
guidelines. Practice Parameters Committee of the American College
of Gastroenterology.
JAMA.
1996;
275
622-629
- 47
Soo S, Moayyedi P, Deeks J, Delaney B, Innes M, Forman D.
Pharmacological
interventions for non-ulcer dyspepsia.
Cochrane Database
Syst Rev.
2000;
CD001960
- 48
Talley N J, Meineche-Schmidt V, Pare P, Duckworth M, Raisanen P, Pap A. et al .
Efficacy
of omeprazole in functional dyspepsia: double-blind, randomized,
placebo-controlled trials (the Bond and Opera studies).
Aliment
Pharmacol Ther.
1998;
12
1055-1065
- 49
Talley N J, Stanghellini V, Heading R C, Koch K L, Malagelada J R, Tytgat G N.
Functional
gastroduodenal disorders.
Gut.
1999;
45
II37-II42
(Suppl 2))
- 50
Talley N J, Weaver A L, Tesmer D L, Zinsmeister A R.
Lack of
discriminant value of dyspepsia subgroups in patients referred for
upper endoscopy.
Gastroenterology.
1993;
105
1378-1386
- 51
Talley N J, Zinsmeister A R, Schleck C D, Melton L J.
Dyspepsia and dyspepsia
subgroups: a population-based study.
Gastroenterology.
1992;
102
1259-1268
- 52
Thumshirn M, Fried M.
Prophylaxe und Therapie
NSAR-induzierter Ulzera - ein Update.
Dtsch Med
Wschr.
2000;
125
975-978
- 53
van Veldhuyzen Z anten
SJ, Cleary C, Talley N J, Peterson T C, Nyren O, Bradley L A. et al .
Drug
treatment of functional dyspepsia: a systematic analysis of trial
methodology with recommendations for design of future trials.
Am
J Gastroenterol.
1996;
91
660-673
- 54
Wolle K, Nilius M, Leodolter A, Müller W A, Malfertheiner P, König W.
Prevalence
of Helicobacter pylori resistance to several antimicrobial agents
in a region of Germany.
Eur J Clin Microbiol Infect Dis.
1998;
17
519-521
- 55
Woolf S H.
Practice
guidelines, a new reality in Medicine.
Arch Intern Med.
1992;
152
946-952
- 56
Yamada T D, Ahnen D, Alpers D H.
NIH
Consensus conference: Helicobacter pylori in peptic ulcer disease.
JAMA.
1994;
272
65-69
- 57
Yeomans N D, Tulassay Z, Juhasz L, Racz I, Howard J M, van Rensburg C J. et al .
A
comparison of omeprazole with ranitidine for ulcers associated with
nonsteroidal antiinflammatory drugs: Acid Suppression Trial. Ranitidine
versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT)
Study Group.
N Engl J Med.
1998;
338
719-726
Korrespondenz
Prof. Dr. med. P. Malfertheiner
Klinik für Gastroenterologie Hepatologie
und Infektionserkrankungen Otto-von-Guericke-Universität
Magdeburg
Leipziger Straße 44
39120 Magdeburg
